L. Falchero

3.0k total citations
71 papers, 1.4k citations indexed

About

L. Falchero is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, L. Falchero has authored 71 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pulmonary and Respiratory Medicine, 46 papers in Oncology and 8 papers in Surgery. Recurrent topics in L. Falchero's work include Lung Cancer Treatments and Mutations (43 papers), Lung Cancer Research Studies (21 papers) and Lung Cancer Diagnosis and Treatment (20 papers). L. Falchero is often cited by papers focused on Lung Cancer Treatments and Mutations (43 papers), Lung Cancer Research Studies (21 papers) and Lung Cancer Diagnosis and Treatment (20 papers). L. Falchero collaborates with scholars based in France, United States and Réunion. L. Falchero's co-authors include David Pérol, C. Chouaïd, M. Pérol, C. Carrié, D. Arpin, L. Claude, C. Ginestet, P. Fournel, Michel Vincent and B. Étienne-Mastroïanni and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

L. Falchero

66 papers receiving 1.4k citations

Peers

Countries citing papers authored by L. Falchero

Since Specialization

Citations

This map shows the geographic impact of L. Falchero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Falchero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Falchero more than expected).

Fields of papers citing papers by L. Falchero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Falchero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Falchero. The network helps show where L. Falchero may publish in the future.

Co-authorship network of co-authors of L. Falchero

This figure shows the co-authorship network connecting the top 25 collaborators of L. Falchero. A scholar is included among the top collaborators of L. Falchero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Falchero. L. Falchero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study 2024 ·BMC Cancer ·B. Mennecier, Jonathan Khalifa, R. Descourt, Laurent Greillier, Charles Naltet, L. Falchero	2
2	Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study 2024 ·The Lancet Respiratory Medicine ·H. Léna, Laurent Greillier, Claire Cropet, Olivier Bylicki, I. Monnet, Clarisse Audigier-Valette, L. Falchero, A. Vergnenègre, (unknown), Margaux Geier, Florian Guisier, S. Hominal, Chrystèle Locher, R. Corre, C. Chouaïd, Charles Ricordel, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	5
3	Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study 2023 ·Targeted Oncology ·(unknown), Philippe Jamme, (unknown), Jean‐Baptiste Assié, Rémi Veillon, H. Doubre, M. Pérol, Florian Guisier, (unknown), C. Decroisette, L. Falchero, R. Corre, Alexis B. Cortot, C. Chouaïd, R. Descourt	3
4	Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study) 2022 ·Clinical Lung Cancer ·Florian Guisier, R. Descourt, (unknown), (unknown), L. Falchero, Rémi Veillon, Alexis B. Cortot, Claire Tissot, C. Chouaïd, C. Decroisette	6
5	Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study) 2021 ·Lung Cancer ·J.B. Auliac, I. Monnet, (unknown), Laurent Greillier, Margaux Geier, L. Falchero, G. Le Garff, R. Lamy, Florian Guisier, Charles Ricordel, C. Chouaïd, A. Vergnenègre	3
6	Reasons Influencing Long-Term Anticoagulant Treatment Beyond 6 Months for Cancer-Associated Thrombosis in USCAT, A 432-Patient Retrospective Non-Interventional Study 2021 ·PubMed ·(unknown), Céline Chapelle, Silvy Laporte, Benjamin Planquette, Laurent Bertoletti, Nicolas Falvo, Françis Couturaud, L. Falchero, I. Mahé, H. L. Helfer, (unknown), Guy Meyer, Isabelle Mahé	2
7	Long-Term Treatment of Cancer-Associated Thrombosis (CAT) Beyond 6 Months in the Medical Practice: USCAT, a 432-Patient Retrospective Non-Interventional Study 2020 ·Cancers ·Isabelle Mahé, (unknown), Céline Chapelle, Silvy Laporte, Benjamin Planquette, Laurent Bertoletti, Françis Couturaud, Nicolas Falvo, L. Falchero, I. Mahé, H. L. Helfer, Jean Chidiac, Guy Meyer	18
8	Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018 2020 ·Journal of Thoracic Oncology ·Florian Guisier, Catherine Dubos‐Arvis, F. Viñas, H. Doubre, Charles Ricordel, Stanislas Ropert, Henri Janicot, Massimo Bernardi, P. Fournel, R. Lamy, M. Pérol, Jérôme Dauba, (unknown), L. Falchero, C. Decroisette, (unknown), C. Chouaïd, Olivier Bylicki	215
9	Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14 2019 ·Advances in Therapy ·J.B. Auliac, Pascal Dô, S. Bayle, H. Doubre, F. Viñas, J. Letreut, L. Falchero, (unknown), P. Thomas, C. Chouaïd	11
10	Evidence of slight improvement in five-year survival in non-small-cell lung cancer over the last 10 years: Results of the French KBP-CPHG real-world studies 2019 ·Bulletin du Cancer ·D. Debieuvre, Chrystèle Locher, Bernard Asselain, C. Dayen, Olivier Molinier, L. Falchero, C. Dujon, B. Delclaux, M Grivaux	15
11	P1.13-09 Efficacy and Tolerance of Osimertinib in Real Word Setting: Results of the French Early Access Program (EXPLORE T790M GFPC Study) 2018 ·Journal of Thoracic Oncology ·J.B. Auliac, M. Pérol, David Planchard, I. Monnet, Marie Wislez, H. Doubre, Florian Guisier, Éric Pichon, Laurent Greillier, Bénédicte Mastroïanni, (unknown), Roland Schött, Sylvestre Le Moulec, Jennifer Arrondeau, Alexis B. Cortot, L. Gérinière, Aldo Renault, Catherine Daniel, L. Falchero, C. Chouaïd	1
12	Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study 2013 ·Journal of Thoracic Oncology ·Olivier Bylicki, Céline Ferlay, C. Chouaïd, A. Lavolé, Fabrice Barlési, Cathérine Dubos, Virginie Westeel, Jacky Créquit, (unknown), A. Vergnenègre, I. Monnet, H. Le Caer, P. Fournel, F. Vaylet, L. Falchero, M. Poudenx, (unknown), David Pérol, Gérard Zalcman, M. Pérol	5
13	Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer 2012 ·Journal of Clinical Oncology ·M. Pérol, C. Chouaïd, David Pérol, Fabrice Barlési, Radj Gervais, Virginie Westeel, Jacky Créquit, H. Léna, A. Vergnenègre, Gérard Zalcman, I. Monnet, H. Le Caer, P. Fournel, L. Falchero, M. Poudenx, F. Vaylet, Céline Ségura‐Ferlay, Mojgan Devouassoux‐Shisheboran, Miquel Tarón, B. Milleron	166
14	PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients: An Economical Analysis of a prospective Phase 2 Study (GFPC 0505) 2011 ·Value in Health ·C. Chouaïd, H. Le Caer, R. Corre, Jacky Créquit, (unknown), L. Falchero, (unknown), A. Vergnenègre	1
15	A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study) 2011 ·British Journal of Cancer ·(unknown), (unknown), Fabrice Barlési, R. Corre, (unknown), Suzanna Bota, L. Falchero, A. Vergnenègre, C. Dujon, (unknown), C. Chouaïd	20
16	Predictive Factors of Late Radiation Fibrosis: A Prospective Study in Non–Small Cell Lung Cancer 2010 ·International Journal of Radiation OncologyBiologyPhysics ·R. Mazeron, B. Étienne-Mastroïanni, David Pérol, D. Arpin, Michel Vincent, L. Falchero, Isabelle Martel‐Lafay, C. Carrié, L. Claude	48
17	Respiratory failure with diffuse bronchiectases and cryoglobulinaemia 2008 ·European Respiratory Journal ·Nicolas Girard, Alexandre Vasiljevic, Vincent Cottin, L. Falchero, David Meyronet, F. Thivolet-Béjui, (unknown)	11
18	Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study 2006 ·Annals of Oncology ·Alexis B. Cortot, L. Gérinière, G. Robinet, Jean-Luc Breton, (unknown), L. Falchero, H. Bérard, (unknown), J.-M. Chavaillon, M. Pérol, P. Bombaron, Catherine Mercier, Pierre Jean Souquet	35
19	Primary sarcomas of the lung 2002 ·Lung Cancer ·B. Étienne-Mastroïanni, L. Falchero, Lara Chalabreysse, R Loire, Dominique Ranchère, Pierre‐Jean Souquet, Jean-François Cordier	88
20	Actinomycose pulmonaire et musculo-cutanée de la cuisse. 1997 ·Revue des Maladies Respiratoires ·L. Falchero, F. Philit, Felix Berger, J.-F. Cordier	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact